@article{6c4afcdd35bc4182a5b7b579196bb4da,
title = "Developing therapies for heart failure withpreservedejection fraction. Current state and future directions",
abstract = "The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.",
keywords = "Epidemiology, Heart failure, Preserved ejection fraction, Prognosis, Treatment",
author = "Javed Butler and Fonarow, {Gregg C.} and Zile, {Michael R.} and Lam, {Carolyn S.} and Lothar Roessig and Schelbert, {Erik B.} and Shah, {Sanjiv J} and Ali Ahmed and Bonow, {Robert O} and Cleland, {John G.F.} and Cody, {Robert J.} and Ovidiu Chioncel and Collins, {Sean P.} and Preston Dunnmon and Gerasimos Filippatos and Lefkowitz, {Martin P.} and Marti, {Catherine N.} and McMurray, {John J.} and Frank Misselwitz and Savina Nodari and Christopher O'Connor and Pfeffer, {Marc A.} and Burkert Pieske and Bertram Pitt and Giuseppe Rosano and Sabbah, {Hani N.} and Michele Senni and Solomon, {Scott D.} and Norman Stockbridge and Teerlink, {John R.} and Georgiopoulou, {Vasiliki V.} and Mihai Gheorghiade",
note = "Funding Information: The opinions and information in this article are those of the authors, and do not represent the views and/or policies of the U.S. Food and Drug Administration. Dr. Fonarow has served as a consultant for Novartis, Medtronic, and Gambro, and has received research support from Gambro, the National Institutes of Health, and the Agency for Healthcare Research and Quality . Dr. Zile has received research support from NHLBI, VA, Alere, Bayer, CVRx, Medtronic, Novartis, Sanofi-Aventis ; and has served as a consultant for Abbott, Alere, Bayer, BG Med, BMS, Cardiome, Celledon, CorAssist, CVRx, GE Health, HDL, Idenex, Intersection Medical, Medtronic, MicroVide, Novartis, ONO Pharma, Sanofi-Aventis, and Up-To-Date. Dr. Lam has served as a consultant for Bayer and Novartis and has received research grant support from Boston Scientific, Medtronic, and Vifor Pharma . Dr. Roessig is an employee of Bayer Pharma. Dr. Schelbert received a Prohance contrast as a gift from Bracco for research purposes. Dr. Cleland has received research funding from Amgen and honoraria from Novartis. Dr. Cody is an employee of Janssen R&D. Dr. Collins has served as a consultant for Novartis, Radiometer, Medtronic, The Medicines Company, Trevena, and Thermo-Fisher Scientific. Dr. Filippatos has served on the steering committee in trials sponsored by Bayer and Corthera. Dr. Lefkowitz is an employee of Novartis. Dr. McMurray was a committee member and co-principal investigator for the PARAGON-HF trial with LCZ696 in HF-PEF, which was sponsored by Novartis . Dr. Misselwitz is an employee of and owns stock for Bayer. Dr. Pfeffer has served as a consultant for Aastrom, Amgen, Bristol-Myers-Squibb, Cerenis, Concert, Genzyme, Hamilton Health Sciences, Keryx, Medtronic, Merck, Novartis, Roche, Servier, Teva, the University of Oxford, and Xoma. Dr. Pieske has received honoraria from Bayer, Servier, Medtronic, Menarini, Daiichi-Sankyo, and Boehringer Ingelheim. Dr. Pitt has served as a consultant for Pfizer, Bayer, Relypsa, Stealth Peptides, and Mesoblast. Dr. Solomon has received research support from and has served as a consultant for Novartis and Bayer. Dr. Teerlink has received research support and consulting fees from Novartis. Dr. Gheorghiade has served as a consultant for Novartis, Bayer, Takeda, and Janssen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",
year = "2014",
month = apr,
doi = "10.1016/j.jchf.2013.10.006",
language = "English (US)",
volume = "2",
pages = "97--112",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "2",
}